Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Luigia Carbone

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Nanomaterials (Basel, Switzerland)|February 25, 2025
Tattoo Ink Metal Nanoparticles: Assessment of Toxicity In Vitro and with a Novel Human Ex Vivo ModelBeatrice Battistini, Daniela Lulli, Beatrice Bocca, et al.
Biomedicines|July 2, 2021
Merkel Cell CarcinomaElena Dellambra, Maria Luigia Carbone, Francesca Ricci, et al.
Aging|April 18, 2020
Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21Laura Mercurio, Daniela Lulli, Francesca Mascia, et al.
Frontiers in Immunology|March 18, 2024
Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitorsMartina Morelli, Maria Luigia Carbone, Giovanni Luca Scaglione, et al.
Frontiers in Pharmacology|January 22, 2026
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case seriesRosa Falcone, Alessandra Frezzolini, Emanuele Bruni, et al.
Biomedicines|December 24, 2021
Reduced Interleukin-17-Expressing Cells in Cutaneous MelanomaAnna Tosi, Lavinia Nardinocchi, Maria Luigia Carbone, et al.
Scientific Reports|April 1, 2022
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patientsMaria Luigia Carbone, Gabriele Madonna, Alessia Capone, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2021
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patientsSofia Verkhovskaia, Francesca Romana Di Pietro, Simona Mastroeni, et al.
Cancers|April 14, 2026
Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell AnalysisAlessia Capone, Maria Luigia Carbone, Simona Mastroeni, et al.
The Journal of Clinical Investigation|November 14, 2017
Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosisMaria Luigia Carbone, Gilliane Chadeuf, Sandrine Heurtebise-Chrétien, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Nanomaterials (Basel, Switzerland)|February 25, 2025
Tattoo Ink Metal Nanoparticles: Assessment of Toxicity In Vitro and with a Novel Human Ex Vivo ModelBeatrice Battistini, Daniela Lulli, Beatrice Bocca, et al.
Biomedicines|July 2, 2021
Merkel Cell CarcinomaElena Dellambra, Maria Luigia Carbone, Francesca Ricci, et al.
Aging|April 18, 2020
Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21Laura Mercurio, Daniela Lulli, Francesca Mascia, et al.
Frontiers in Immunology|March 18, 2024
Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitorsMartina Morelli, Maria Luigia Carbone, Giovanni Luca Scaglione, et al.
Frontiers in Pharmacology|January 22, 2026
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case seriesRosa Falcone, Alessandra Frezzolini, Emanuele Bruni, et al.
Biomedicines|December 24, 2021
Reduced Interleukin-17-Expressing Cells in Cutaneous MelanomaAnna Tosi, Lavinia Nardinocchi, Maria Luigia Carbone, et al.
Scientific Reports|April 1, 2022
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patientsMaria Luigia Carbone, Gabriele Madonna, Alessia Capone, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2021
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patientsSofia Verkhovskaia, Francesca Romana Di Pietro, Simona Mastroeni, et al.
Cancers|April 14, 2026
Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell AnalysisAlessia Capone, Maria Luigia Carbone, Simona Mastroeni, et al.
The Journal of Clinical Investigation|November 14, 2017
Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosisMaria Luigia Carbone, Gilliane Chadeuf, Sandrine Heurtebise-Chrétien, et al.
Pageof 3